Amplia Therapeutics Limited

ATX.AX

Biotechnology · Healthcare

Price

A$0.15

+0.00 (+0.00%)

Market Cap

A$77.0M

Exchange

Australian Securities Exchange

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+222.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 145.5M (2022) → 469.6M (2026)

Winston Score History

The full picture

Amplia Therapeutics is a small Australian biotechnology company focused on developing drugs to treat cancer. It does not sell products yet — instead, it runs clinical trials testing experimental medicines that aim to stop tumors from spreading. Its main focus is on a class of proteins called FAK (focal adhesion kinase) inhibitors, which may help treat pancreatic cancer and other hard-to-treat solid tumors.

The company does not currently earn revenue from product sales, which explains its zero gross margin. It is funded primarily through equity raises and grants, a common model for early-stage drug developers. Amplia operates mainly in Australia and conducts trials in partnership with research institutions. The key risk is that most experimental cancer drugs fail in clinical trials, and if its lead drug candidate does not show strong results in ongoing studies, the company may struggle to attract the funding needed to continue operations.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-100.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+33.7% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

A$9M/ year

↑ Rising (+21% vs prior year)

R&D investment increasing — building for the future

Insider Activity

18.2%ownership

↑ Rising

Insiders increasing their stake — aligned with shareholders

Cash Runway

~6 years

A$28M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

A$28M cash & investments at current burn rate

Revenue declining

Amplia Therapeutics Limited's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

Data not available

Profit after running costs

Operating Margin

N/A

Data not available

Return on the money invested

ROCE

-33.3%

Weak — -33.3% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-100.0%

Shrinking sales (-100.0% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.00

Conservative — low debt load (0.00)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial